Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages 4482-4486

  Santini, Daniele ^a   Vincenzi, Bruno ^a   Galluzzo, Sara ^a   Battistoni, Fabrizio ^a   Rocci, Laura ^a   Venditti, Olga ^a   Schiavon, Gaia ^a   Angeletti, Silvia ^a   Uzzalli, Federica ^a   Caraglia, Michele ^b   Dicuonzo, Giordano ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COLECALCIFEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547653957     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0551     Document Type: Article

References (28)

1. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
2. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis inmurine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
3. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br J Haematol 1997;98:665-72.
4. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, ZA, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-34.
5. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-93.
6. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91.
7. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of ZA in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
8. Rosen LS, Gordon D, Tchekmedyian S, et al. ZA versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the ZA Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
9. Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468-76.
10. Santini D, Schiavon G, Angeletti S, et al. Last generation of amino-bisphosphonates (N-BPs) and cancer angiogenesis: a new role for these drugs? Recent patents on anti-cancer drug discovery 2006.
11. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound ZA. J Pharmacol Exp Ther 2002;302:1055-61.
12. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
13. Bezzi M , Hasmim M, Bieler G, Dormon O, Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. JBiol Chem 2003;278:43603-14.
14. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2002;8:1080-4.
15. Santini D, Vincenzi B, Dicuonzo G, et al. ZA induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7.
16. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
17. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
18. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
19. Daubinè F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30.
20. Caraglia M, Santini D, Marra M, et al. Emerging anticancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006;13:7-26.
21. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000;6:3147-52.
22. Gunsilius E, Petzer A, Stockhammer G, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000;58:169-74.
23. Gouin F, Ory B, Redini F, Heymann D. ZA slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006;119:980-4.
24. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. ZA suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005;104:2522-9.
25. Santini D, Caraglia M, Vincenzi B, et al. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 2006;3:325-38.
26. Giraudo E, Inoue M, Hanahan D. An aminobisphosphonate targets MMP-9 - expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114:623-33.
27. Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation dependent signaling pathways. J Thromb Haemost 2007;5:166-73.
28. Hafner C, Reichle A, Vogt T. New indications for established drugs: combined tumor-stroma -targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets 2005;5:393-419.